Melitraxol Tablet contains a combination of Flupenthixol (0.5 mg) and Melitracen (10 mg), formulated for the management of depressive disorders and associated anxiety symptoms. Flupenthixol is a typical antipsychotic agent belonging to the thioxanthene class, exerting its therapeutic effects primarily through dopamine receptor antagonism, which helps in modulating mood and psychotic symptoms. Melitracen, a tricyclic antidepressant, enhances neurotransmitter activity by inhibiting the reuptake of serotonin and norepinephrine, thereby improving mood and alleviating depressive symptoms. The synergistic action of these two active ingredients provides an effective approach in treating patients with mild to moderate depression, particularly when accompanied by anxiety or agitation. Melitraxol is indicated for short-term use under medical supervision, as prolonged administration may increase the risk of adverse effects. Common side effects may include dry mouth, dizziness, gastrointestinal disturbances, and extrapyramidal symptoms, necessitating careful monitoring. It is contraindicated in patients with hypersensitivity to either component, severe liver or kidney impairment, and certain cardiovascular conditions. Dosage should be individualized based on clinical response and tolerability, with caution advised in elderly patients and those with a history of seizures. Melitraxol should be used as part of a comprehensive treatment plan including psychological support.